Primary hepatocellular carcinoma (HCC) is a prevalent world-wide malignancy. Half of the newly developed HCC occurs in China. Optimizing the strategies for high-risk surveillance and early diagnosis is pivotal for improving 5-year survival. Constructing the scientific non-invasive determination technologies feasible for medical and healthcare institutions is a key route for elevating the efficacies in HCC diagnosis and follow-up. Based on the international and Chinese guidelines,expert consensus statements,literatures and evidence-based clinical practice experiences,this consensus published by the Clinical Laboratory Society of Chinese Association for Rehabilitation Medicine puts forward the clinical implications,application subjects,determination techniques and result interpretations for GALAD and GALAD-like models based on alpha-fetoprotein (AFP),alpha-fetoprotein heterogeneity-L3%(AFP-L3%),and des-gamma-carboxy prothrombin(DCP). The compile of this consensus statement aims to address and push the reasonable model application of the triple-biomarker(AFP, AFP-L3%, DCP)determinations thus to maximize the clinical efficacies and help improving HCC high-risk surveillance,early diagnosis and prognosis.